Bioavailability assessment from pharmacologic data: Method and clinical evaluation

Grazia Stagni, Alexander M Shepherd, Yanjuan Liu, William R. Gillespie

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A novel method is described for assessing drug bioavailability from pharmacologic data. The method is based upon a generalized model for the relationship between the observed effect (E) and the input rate (f): E =φ(C(eδ) * f)) were * denotes convolution, c(eδ) is effect site unit impulse response ('amount' of drug at the effect site resulting from the instantaneous input of a unit amount of drug) and φ is transduction function (relates 'amount' of drug at the effect site to E). The functions φ and c(eδ) are expressed as cubic splines for maximum versatility. Pharmacologic data collected after the administration of two different doses by iv infusion are analyzed simultaneously to estimate the function parameters. This experimental design addresses the fact that φ and c(eδ) cannot be uniquely estimated from the results of a single dose experiment. The unknown f from a test treatment is then estimated by applying an implicit deconvolution method to the pharmacologic data collected during that treatment. The method was tested with simulated data. The method and the model were further evaluated by application to a clinical study of verapamil (V) pharmacodynamics in 6 healthy volunteers. Simulations showed that the method is accurate and precise in the presence of a high degree of measurement error, but large intrasubject variability in the model functions can result in biased estimates of the amount absorbed. The method produced reasonably accurate estimates of the V input rate and systemic availability (F) in the 6 human volunteers though there was a trend towards underestimation (estimated total F% = 93.6 ± 14 vs. the true F% of 100).

Original languageEnglish (US)
Pages (from-to)349-362
Number of pages14
JournalJournal of Pharmacokinetics and Biopharmaceutics
Volume25
Issue number3
DOIs
StatePublished - 1997

Fingerprint

Biological Availability
Pharmaceutical Preparations
Verapamil
Volunteers
Healthy Volunteers
Research Design
Therapeutics

Keywords

  • Bioavailability
  • Computer simulation
  • Pharmacodynamics
  • Pharmacokinetics
  • Pharmacologic data
  • Verapamil

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology

Cite this

Bioavailability assessment from pharmacologic data : Method and clinical evaluation. / Stagni, Grazia; Shepherd, Alexander M; Liu, Yanjuan; Gillespie, William R.

In: Journal of Pharmacokinetics and Biopharmaceutics, Vol. 25, No. 3, 1997, p. 349-362.

Research output: Contribution to journalArticle

Stagni, Grazia ; Shepherd, Alexander M ; Liu, Yanjuan ; Gillespie, William R. / Bioavailability assessment from pharmacologic data : Method and clinical evaluation. In: Journal of Pharmacokinetics and Biopharmaceutics. 1997 ; Vol. 25, No. 3. pp. 349-362.
@article{91eb5d4e609a4ab2b766e06666816faf,
title = "Bioavailability assessment from pharmacologic data: Method and clinical evaluation",
abstract = "A novel method is described for assessing drug bioavailability from pharmacologic data. The method is based upon a generalized model for the relationship between the observed effect (E) and the input rate (f): E =φ(C(eδ) * f)) were * denotes convolution, c(eδ) is effect site unit impulse response ('amount' of drug at the effect site resulting from the instantaneous input of a unit amount of drug) and φ is transduction function (relates 'amount' of drug at the effect site to E). The functions φ and c(eδ) are expressed as cubic splines for maximum versatility. Pharmacologic data collected after the administration of two different doses by iv infusion are analyzed simultaneously to estimate the function parameters. This experimental design addresses the fact that φ and c(eδ) cannot be uniquely estimated from the results of a single dose experiment. The unknown f from a test treatment is then estimated by applying an implicit deconvolution method to the pharmacologic data collected during that treatment. The method was tested with simulated data. The method and the model were further evaluated by application to a clinical study of verapamil (V) pharmacodynamics in 6 healthy volunteers. Simulations showed that the method is accurate and precise in the presence of a high degree of measurement error, but large intrasubject variability in the model functions can result in biased estimates of the amount absorbed. The method produced reasonably accurate estimates of the V input rate and systemic availability (F) in the 6 human volunteers though there was a trend towards underestimation (estimated total F{\%} = 93.6 ± 14 vs. the true F{\%} of 100).",
keywords = "Bioavailability, Computer simulation, Pharmacodynamics, Pharmacokinetics, Pharmacologic data, Verapamil",
author = "Grazia Stagni and Shepherd, {Alexander M} and Yanjuan Liu and Gillespie, {William R.}",
year = "1997",
doi = "10.1023/A:1025775809382",
language = "English (US)",
volume = "25",
pages = "349--362",
journal = "Journal of Pharmacokinetics and Pharmacodynamics",
issn = "1567-567X",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Bioavailability assessment from pharmacologic data

T2 - Method and clinical evaluation

AU - Stagni, Grazia

AU - Shepherd, Alexander M

AU - Liu, Yanjuan

AU - Gillespie, William R.

PY - 1997

Y1 - 1997

N2 - A novel method is described for assessing drug bioavailability from pharmacologic data. The method is based upon a generalized model for the relationship between the observed effect (E) and the input rate (f): E =φ(C(eδ) * f)) were * denotes convolution, c(eδ) is effect site unit impulse response ('amount' of drug at the effect site resulting from the instantaneous input of a unit amount of drug) and φ is transduction function (relates 'amount' of drug at the effect site to E). The functions φ and c(eδ) are expressed as cubic splines for maximum versatility. Pharmacologic data collected after the administration of two different doses by iv infusion are analyzed simultaneously to estimate the function parameters. This experimental design addresses the fact that φ and c(eδ) cannot be uniquely estimated from the results of a single dose experiment. The unknown f from a test treatment is then estimated by applying an implicit deconvolution method to the pharmacologic data collected during that treatment. The method was tested with simulated data. The method and the model were further evaluated by application to a clinical study of verapamil (V) pharmacodynamics in 6 healthy volunteers. Simulations showed that the method is accurate and precise in the presence of a high degree of measurement error, but large intrasubject variability in the model functions can result in biased estimates of the amount absorbed. The method produced reasonably accurate estimates of the V input rate and systemic availability (F) in the 6 human volunteers though there was a trend towards underestimation (estimated total F% = 93.6 ± 14 vs. the true F% of 100).

AB - A novel method is described for assessing drug bioavailability from pharmacologic data. The method is based upon a generalized model for the relationship between the observed effect (E) and the input rate (f): E =φ(C(eδ) * f)) were * denotes convolution, c(eδ) is effect site unit impulse response ('amount' of drug at the effect site resulting from the instantaneous input of a unit amount of drug) and φ is transduction function (relates 'amount' of drug at the effect site to E). The functions φ and c(eδ) are expressed as cubic splines for maximum versatility. Pharmacologic data collected after the administration of two different doses by iv infusion are analyzed simultaneously to estimate the function parameters. This experimental design addresses the fact that φ and c(eδ) cannot be uniquely estimated from the results of a single dose experiment. The unknown f from a test treatment is then estimated by applying an implicit deconvolution method to the pharmacologic data collected during that treatment. The method was tested with simulated data. The method and the model were further evaluated by application to a clinical study of verapamil (V) pharmacodynamics in 6 healthy volunteers. Simulations showed that the method is accurate and precise in the presence of a high degree of measurement error, but large intrasubject variability in the model functions can result in biased estimates of the amount absorbed. The method produced reasonably accurate estimates of the V input rate and systemic availability (F) in the 6 human volunteers though there was a trend towards underestimation (estimated total F% = 93.6 ± 14 vs. the true F% of 100).

KW - Bioavailability

KW - Computer simulation

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Pharmacologic data

KW - Verapamil

UR - http://www.scopus.com/inward/record.url?scp=0031440810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031440810&partnerID=8YFLogxK

U2 - 10.1023/A:1025775809382

DO - 10.1023/A:1025775809382

M3 - Article

C2 - 9474532

AN - SCOPUS:0031440810

VL - 25

SP - 349

EP - 362

JO - Journal of Pharmacokinetics and Pharmacodynamics

JF - Journal of Pharmacokinetics and Pharmacodynamics

SN - 1567-567X

IS - 3

ER -